A consensus document from eight clinicians who actually use ketogenic diet to treat serious mental illness in practice — Georgia Ede, Chris Palmer, Shebani Sethi, Lori Calabrese, Nicole Laurent, Iain Campbell, Matthew Bernstein, and dietitian Beth Zupec-Kania. Using the modified Delphi method, they reached 100% consensus on 33 practical statements for running a ketogenic intervention in schizophrenia, bipolar disorder, or major depression: patient selection, supplementation, monitoring requirements, and when not to do this. The piece doesn’t prove the diet works — it assumes the underlying evidence and focuses on the clinical how-to. Closest thing to a practical treatment guideline metabolic psychiatry has right now.
Read full paper →
A short editorial using the Campbell bipolar pilot to make a bigger argument: psychiatric illnesses share metabolic problems at their root, and a ketogenic diet is one of several metabolic interventions that may treat them. Palmer points to over 50 case reports and pilot trials covering more than 1,900 participants across bipolar, schizophrenia, depression, autism, and Alzheimer’s. He floats the idea that the so-called “p-factor” linking psychiatric disorders is really metabolic dysfunction in the brain. He also covers parallel interventions worth watching — GLP-1 agonists for psychiatric symptoms, mitochondrial-support supplements like carnitine and creatine. Honest about barriers: dietary research is hard, insurance doesn’t cover it, and funding is mostly philanthropic (the Baszucki Group has put in $60 million so far).
Read full paper →
Palmer’s short BJPsych Advances commentary arguing that metabolic dysfunction in psychiatric patients isn’t a side issue. The standard view treats obesity, diabetes, and metabolic syndrome as comorbidities that come along with serious mental illness — things to manage, but not the main problem. Palmer argues this gets it backwards: mitochondrial dysfunction sits underneath both the metabolic problems and the psychiatric symptoms; they’re different expressions of the same underlying breakdown. The therapeutic implication: if the root is metabolic, then a treatment that fixes metabolism (like a ketogenic diet) should help both body and brain at once. Short version of the brain energy thesis.
Read full paper →
A 2025 review covering everything published on the ketogenic diet across the major psychiatric and neurological conditions. The authors walk through the shared mechanisms — mitochondrial dysfunction, oxidative stress, inflammation, brain glucose hypometabolism, and glutamate/GABA imbalance — and how a ketogenic diet improves all five. They then summarize the clinical evidence so far for each condition: schizophrenia and schizoaffective disorder, bipolar, depression, anxiety, Alzheimer’s, autism, somatic disorders, eating disorders, and alcohol use disorder. The argument: the same mechanisms keep showing up across this whole spectrum, which means the same treatment may work across the spectrum. Closest thing to a state-of-the-field summary that exists right now.
Read full paper →
A 2020 review arguing that schizophrenia, depression, bipolar disorder, and binge eating disorder aren’t really “neurochemical” diseases but neurometabolic ones — sharing brain glucose hypometabolism, neurotransmitter imbalances, oxidative stress, and inflammation. The authors walk through how a ketogenic diet hits all four directly, and pull together the clinical evidence available at the time (case reports, observational data, animal models). Part of the foundational metabolic-psychiatry literature: it reframes psychiatric illness as a metabolic problem rather than a chemical imbalance, and most of the current ketogenic mental health trials are built on this framework.
Read full paper →
A 2020 International Journal of Neuropsychopharmacology review focused on serious mental illness: schizophrenia, bipolar disorder, and treatment-resistant depression. The authors pull together everything published to that point — case reports of medication-resistant patients going into full remission on a ketogenic diet, animal models showing improvements in schizophrenia-like symptoms, and the broader metabolic literature linking these conditions to mitochondrial and energy-metabolism problems. Short but heavy. The paper most other reviews cite as the inflection point for the field, making the case for why the next decade of psychiatric research should take metabolic interventions seriously.
Read full paper →
A short Journal of Clinical Psychiatry review walking through what’s known about diet as a psychiatric intervention. Highlights the SMILES trial — the first RCT of dietary intervention for major depression — where 32% of people on a Mediterranean diet hit full remission after 12 weeks compared to 8% in the social support control. The author also covers early ketogenic diet signals in serious mental illness, gut microbiome literature, and short-term fasting. The takeaway: psychiatry has spent decades acting like food doesn’t matter, and that view is almost certainly wrong. Starting point rather than final answer, but one of the earliest papers to put food on the same shelf as medication in a mainstream psychiatry journal.
Read full paper →
A review titled “From mice to men” walking through the evidence base for ketogenic diet across the major neurodegenerative and psychiatric disorders. The authors split it cleanly: in animal models the diet works strongly across schizophrenia, autism, anxiety, depression, Alzheimer’s, and Parkinson’s, with consistent improvements in behavior and brain function. In humans, the evidence is thinner — mostly case reports and small pilots, with the strongest signals in Alzheimer’s, psychotic disorders, and autism spectrum. The honest takeaway: the diet looks like it should work and probably does, but the field can’t say so with confidence until proper RCTs are done. A useful map of what’s solid evidence and what’s still hopeful.
Read full paper →
